Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer.
Twelve patients with metastatic colon cancer were treated with 131I-chimeric B72.3 (IgG-4) at total doses of 28 or 36 mCi/m2 in two or three weekly fractions. Bone marrow suppression was the only significant side effect. The degree of bone marrow suppression adjusted for whole-body dose was modestly but statistically significantly (p = 0.04) less than that seen with identical doses given as a single infusion for the total dose of 36 mCi/m2. Nine of twelve patients developed an antibody response to ch B72.3, which altered the kinetics of radiolabeled antibody in four patients given a second course of therapy. One patient had a minor response that lasted 4 mo. Fractionation of this particular radiolabeled antibody at the dose schedule used produced a modest increase in the therapeutic window in regard to administered dose.
Meredith
R F
RF
Department of Radiation Oncology, University of Alabama, Birmingham 35294-3300.
Khazaeli
M B
MB
Liu
T
T
Plott
G
G
Wheeler
R H
RH
Russell
C
C
Colcher
D
D
Schlom
J
J
Shochat
D
D
LoBuglio
A F
AF
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology; D000917:Antibody Formation; D001855:Bone Marrow Diseases / Q000209:etiology; D003110:Colonic Neoplasms / Q000097:blood / Q000276:immunology / Q000532:radiotherapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010976:Platelet Count; D016499:Radioimmunotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes